ASCLEPIX THERAPEUTICS

AsclepiX Therapeutics is a clinical-stage biopharmaceutical company based in Baltimore, Maryland. The company employs 7 people and has generated $2.5 million in revenue. AsclepiX Therapeutics focuses on identifying and developing peptides for the treatment of retinal diseases. They utilize computational biology from Johns Hopkins University to advance their research. Their lead candidate, AXT107, targets two key pathways involved in retinal vascular diseases: pro-angiogenic vascular endothelial growth factor receptor 2 (VEGFR2) and the vessel stabilizing receptor tyrosine kinase (Tie2). AsclepiX Therapeutics differentiates itself through its use of computational biology and its focus on developing novel peptide-based therapies for retinal diseases. For more information, visit asclepix.com.